Skip to main contentSkip to navigation
Sirius Investors
Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLI
NASDAQHealthcare

Denali Therapeutics Inc. (DNLI) Investment Research Dashboard

About Denali Therapeutics Inc. (DNLI) stock analysis

Get live DNLI stock price $23.58, comprehensive Denali Therapeutics Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time DNLI stock data and investment insights.

23.58
0.04%Today
Market Cap
3.74B
Volume
1.40M
52W High
27.30
52W Low
12.58

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initiall...

Company Information

CEO
Ryan J. Watts
Sector
Healthcare
Industry
Biotechnology
Employees
443

Contact Information

Address
161 Oyster Point Boulevard
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Denali Therapeutics Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Denali Therapeutics Inc.
  • Investors should consider how Denali Therapeutics Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

3.74B

P/E Ratio (TTM)

-8.19

Beta

0.96

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

64/100 ⭐⭐⭐⭐

Overall
+0.3%
NYSE
+0.3%
NASDAQ
+0.3%
Sector1D1W1MP/EScore
Financial Services+1.7%+2.6%+3.8%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.3%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive+0.5%+2.6%+1.5%30.0
70/100⭐⭐⭐⭐⭐
Basic Materials+1.2%+2.0%+0.6%25.4
66/100⭐⭐⭐⭐
Healthcare+0.3%+0.9%+1.2%24.0
64/100⭐⭐⭐⭐
Utilities-0.1%+0.9%-3.6%27.0
47/100⭐⭐⭐
Real Estate+0.3%+0.8%-1.7%29.4
46/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.2
34/100⭐⭐
Consumer Cyclical+0.6%-1.4%-5.7%43.0
19/100
Industrials+0.5%+0.3%-10.0%30.2
17/100
Technology+0.7%-1.5%-7.1%40.8
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.